|
|
Lilly Reports FourthQuarter and FullYear 2014 Results, Updates 2015 Guidance
INDIANAPOLIS, Jan. 30, 2015
Fourthquarter 2014 revenue declined 12 percent driven by the impact of U.S. patent expirations for Cymbalta and Evista
and the unfavorable impact of foreign exchange rates, partially offset by strong volume growth in several other
products.
... Lire le communiqué |
|
| |
|
| |
|
|
Lilly Provides Update on Strategy and Announces 2015 Financial Guidance
- The company describes refinements to its innovation-based strategy, including
greater focus on core therapeutic areas and key geographies.
- The company provides a mid-term financial outlook that includes year-on-year
revenue growth, expanding margins, investments to maintain R&D output and
deployment of capital to... Lire le communiqué |
|
| |
|
| |
|
|
Lilly Reports Third-Quarter 2014 Results
INDIANAPOLIS, Oct. 23, 2014 --
* Third-quarter 2014 revenue declined 16 percent driven by the impact of U.S.
patent expirations for Cymbalta and Evista, partially offset by volume growth
in most other products.
* Reported operating expenses declined 4 percent as ongoing cost containment
initiatives were partially offset by expense... Lire le communiqué |
|
| |
|
| |
|
|
Lilly Reports Second-Quarter 2014 Results
INDIANAPOLIS, July 24, 2014 --
. Second-quarter 2014 revenue declined 17 percent driven by the impact of U.S.
patent expirations for Cymbalta and Evista, partially offset by volume growth
in several other products.
. Expense management initiatives resulted in 11 percent OPEX reduction,
partially offsetting revenue declines.
.... Lire le communiqué |
|
| |
|
| |
|
|
Eli Lilly And Company Files Form 10-K
INDIANAPOLIS, April 30, 2014 -- Eli Lilly and Company (NYSE / Euronext Paris /
SIX: LLY) today informs its shareholders its Annual Report on Form 10-K for its
fiscal year ended December 31, 2013 has been filed with the U.S. Securities and
Exchange Commission ("SEC").
Lilly makes available free of charge on its website, its Annual Report on... Lire le communiqué |
|
| |
|
| |
|
|
Eli Lilly and Company Calls Stockholders Meeting
INDIANAPOLIS, April 30, 2014 -- Eli Lilly and Company (NYSE / Euronext Paris /
SIX: LLY) today informs its shareholders that it is holding the 2014 Annual
General Meeting of stockholders of Lilly on May 5, 2014 at 11:00 a.m. at The
Lilly Center Auditorium, Lilly Corporate Center, Indianapolis, Indiana 46285,
for the following purposes:
*... Lire le communiqué |
|
| |
|
| |
|
|
Eli Lilly and Company Files Form 10-Q
INDIANAPOLIS, April 30, 2014 -- Eli Lilly and Company (NYSE / Euronext Paris /
SIX: LLY) today informs its shareholders its Quarterly Report on Form 10-Q for
the quarterly period ended March 31, 2014 has been filed with the U.S.
Securities and Exchange Commission ("SEC").
Lilly makes available free of charge on its website, its Annual Report on... Lire le communiqué |
|
| |
|
| |
